MREO
Price
$1.80
Change
-$0.02 (-1.10%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
288.03M
132 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$31.85
Change
-$0.98 (-2.99%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
3.07B
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MREO vs RARE

Header iconMREO vs RARE Comparison
Open Charts MREO vs RAREBanner chart's image
Mereo BioPharma Group
Price$1.80
Change-$0.02 (-1.10%)
Volume$22.38K
Capitalization288.03M
Ultragenyx Pharmaceutical
Price$31.85
Change-$0.98 (-2.99%)
Volume$15.99K
Capitalization3.07B
MREO vs RARE Comparison Chart in %
MREO
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MREO vs. RARE commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (MREO: $1.81 vs. RARE: $31.85)
Brand notoriety: MREO and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 103% vs. RARE: 70%
Market capitalization -- MREO: $288.03M vs. RARE: $3.07B
MREO [@Biotechnology] is valued at $288.03M. RARE’s [@Biotechnology] market capitalization is $3.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, MREO is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 3 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • MREO’s TA Score: 3 bullish, 7 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RARE is a better buy in the short-term than MREO.

Price Growth

MREO (@Biotechnology) experienced а -1.63% price change this week, while RARE (@Biotechnology) price change was -5.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

MREO is expected to report earnings on Apr 01, 2026.

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.07B) has a higher market cap than MREO($288M). RARE YTD gains are higher at: -24.293 vs. MREO (-48.286). MREO has higher annual earnings (EBITDA): -47.49M vs. RARE (-435.33M). RARE has more cash in the bank: 477M vs. MREO (56.1M). MREO has less debt than RARE: MREO (601K) vs RARE (36.3M). RARE has higher revenues than MREO: RARE (610M) vs MREO (500K).
MREORAREMREO / RARE
Capitalization288M3.07B9%
EBITDA-47.49M-435.33M11%
Gain YTD-48.286-24.293199%
P/E RatioN/AN/A-
Revenue500K610M0%
Total Cash56.1M477M12%
Total Debt601K36.3M2%
FUNDAMENTALS RATINGS
MREO vs RARE: Fundamental Ratings
MREO
RARE
OUTLOOK RATING
1..100
7457
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (73) in the null industry is in the same range as RARE (97) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

MREO's Profit vs Risk Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

MREO's SMR Rating (97) in the null industry is in the same range as RARE (99) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (59) in the Biotechnology industry is in the same range as MREO (64) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (1) in the null industry is significantly better than the same rating for RARE (100) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREORARE
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend about 1 month ago
81%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 13 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APSRX16.770.06
+0.36%
NYLI Fiera SMID Growth Class A
BIVIX17.03N/A
N/A
Invenomic Institutional
FIQKX13.53N/A
N/A
Fidelity Advisor International Value Z
VTCIX168.90N/A
N/A
Vanguard Tax-Managed Capital App I
LQFLX14.92N/A
N/A
Lord Abbett Focused Large Cap Value R3

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-2.99%
MREO - RARE
71%
Closely correlated
-0.55%
NRIX - RARE
50%
Loosely correlated
+13.09%
NUVL - RARE
48%
Loosely correlated
+2.71%
IONS - RARE
48%
Loosely correlated
-0.67%
RGNX - RARE
48%
Loosely correlated
-2.84%
More